These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 32611557)
1. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557 [TBL] [Abstract][Full Text] [Related]
2. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716 [TBL] [Abstract][Full Text] [Related]
3. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. Liu G; Luo P Front Immunol; 2023; 14():1208788. PubMed ID: 37334375 [TBL] [Abstract][Full Text] [Related]
4. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742 [TBL] [Abstract][Full Text] [Related]
5. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]. Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731 [TBL] [Abstract][Full Text] [Related]
6. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Melero I; Sanmamed MF; Glez-Vaz J; Luri-Rey C; Wang J; Chen L Cancer Discov; 2023 Mar; 13(3):552-569. PubMed ID: 36576322 [TBL] [Abstract][Full Text] [Related]
7. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Chester C; Sanmamed MF; Wang J; Melero I Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009 [TBL] [Abstract][Full Text] [Related]
9. Rationale for anti-CD137 cancer immunotherapy. Makkouk A; Chester C; Kohrt HE Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393 [TBL] [Abstract][Full Text] [Related]
10. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288 [TBL] [Abstract][Full Text] [Related]
12. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401 [TBL] [Abstract][Full Text] [Related]
13. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases. Wong HY; Schwarz H J Autoimmun; 2020 Aug; 112():102499. PubMed ID: 32505443 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand. Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858 [TBL] [Abstract][Full Text] [Related]
15. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282 [TBL] [Abstract][Full Text] [Related]
18. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity. Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872 [TBL] [Abstract][Full Text] [Related]
19. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480 [TBL] [Abstract][Full Text] [Related]
20. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage? Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]